Company / Cost of Revenue
Elicio Therapeutics, Inc. Cost of Revenue History
FY2021-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$433.0K
FY2022
5-year range
$433.0K / $1.2M
FY2021-FY2022
Trend
-63.6%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$433,000 in FY2022.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, cost of revenue decreased 63.6% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.36 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $433.0K | -63.6% |
| FY2021 | $1.2M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026